Product Information
RYBELSUS 3 MG TABLET is a brand product labeled by Novo Nordisk, priced at $33.1674 per EA under NDC 00169430330. Its NADAC has been published 223 times since Mar 23, 2022.
Strength
3 mg/1
Manufacturer
Novo NordiskNDC
00169430330
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
SEMAGLUTIDEApproval Type
New Drug (NDA)
FDA Application
NDA213051On Market Since
9/20/2019
Pharmacological Classes
Price Statistics
The NADAC for RYBELSUS 3 MG TABLET has been published 223 times since Mar 23, 2022, and over the history we have for it it has risen 16.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $33.1674 per EA |
|---|---|
| All-time high | $33.1674 (Jun 24, 2026) |
| All-time low | $28.5340 (Mar 23, 2022) |
| 52-week high | $33.1674 |
| 52-week low | $32.1645 |
| Median price | $31.0573 |
| Average price | $30.8444 |
| Largest weekly change | +4.9% (Jan 11, 2023) |
| Weeks tracked | 223 |
| Tracking since | Mar 23, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the Oral Semaglutide market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of RYBELSUS 3 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RYBELSUS 3 MG TABLET, manufactured by Novo Nordisk, is $33.1674 per EA (NDC 00169430330), effective Jun 24, 2026.
How has the price of RYBELSUS 3 MG TABLET changed over time?
Over the history we have for it, the NADAC for RYBELSUS 3 MG TABLET has risen 16.2%. It has been tracked across 223 weekly CMS publications since Mar 23, 2022.
What are the highest and lowest recorded NADAC prices for RYBELSUS 3 MG TABLET?
Since Mar 23, 2022, the NADAC for RYBELSUS 3 MG TABLET has ranged from a low of $28.5340 (Mar 23, 2022) to a high of $33.1674 (Jun 24, 2026), with a median of $31.0573 per EA.
Are there cheaper alternatives to RYBELSUS 3 MG TABLET?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of RYBELSUS 3 MG TABLET, so no direct lower-cost alternative is listed.
Who manufactures RYBELSUS 3 MG TABLET?
RYBELSUS 3 MG TABLET (NDC 00169430330) is labeled by Novo Nordisk, and CMS classifies it as a brand product.
Related Drugs
Same classification